Market Overview
The Australia vaccine market size was valued at USD 1,305.43 Million in 2025 and is expected to advance to USD 2,785.10 Million by 2034, growing at a compound annual growth rate of 8.78% during 2026–2034. This growth is fueled by the National Immunization Program, rising infectious diseases, technological advances in vaccines, and significant government investments in pandemic preparedness. Australia is emerging as a regional leader in vaccine manufacturing and distribution, driven by demographic aging and increased public health focus.
How AI is Reshaping the Future of Australia Vaccine Market:
- AI enables enhanced vaccine development by accelerating analysis of infectious disease patterns, aiding in tailored vaccine formulations aligned with the National Immunisation Program priorities.
- AI-driven analytics optimize manufacturing processes at facilities like CSL Seqirus and Moderna’s mRNA vaccine plant, improving production efficiency and scaling capabilities.
- Deployment of AI in supply chain logistics helps address vulnerabilities from international dependencies by improving cold chain management and delivery forecasting.
- AI-facilitated data integration supports the National Immunization Strategy’s aims to improve equitable access and sustain immunization uptake across diverse populations.
- Through AI-powered public health surveillance, real-time tracking of disease prevalence supports rapid response to outbreaks, enhancing vaccine demand forecasting.
- AI automates pharmacist and intern pharmacist training programs, expanding immunization workforce capacity to meet increased vaccination demand under programs such as NIPVIP.
Grab a sample. PDF of this report: https://www.imarcgroup.com/australia-vaccine-market/requestsample
Market Growth Factors
The Australia vaccine market is witnessing substantial growth propelled by significant government investment in domestic vaccine manufacturing infrastructure. Notably, the CSL Seqirus facility in Tullamarine bolsters the Southern Hemisphere’s vaccine production, while Moderna’s partnership to build a cutting-edge mRNA facility in Victoria enhances sovereign manufacturing capabilities with an expected annual capacity of 100 million doses. These advancements strengthen pandemic preparedness by reducing import dependence and accelerating production scale-up, aligning with the National Immunization Strategy’s goals.
Another critical growth factor is the expansion of the National Immunization Program (NIP), which continuously incorporates new vaccines and broadens eligibility. The February introduction of the National RSV Mother and Infant Protection Program, providing free maternal RSV vaccination via the Abrysvo vaccine and complementary state-funded monoclonal antibody therapy for infants, significantly enhances immunization coverage. Additionally, the transition from Prevenar 13 to the expanded-valency Prevenar 20 on the childhood schedule broadens protection against pneumococcal diseases, reflecting ongoing program evolution to address emerging health needs.
Rising infectious disease burden is driving immunization demand, underscored by the record-breaking 349,728 influenza alerts during 2024, identified as the worst flu season since 2019. Heightened awareness among healthcare providers, policymakers, and the public fosters investments in immunization infrastructure and expansion of vaccination programs. The resurgence of measles across the Asia-Pacific also fuels catch-up campaigns, underscoring the urgency for sustained vaccine coverage and program adaptation to counter emerging threats.
Market Segmentation
Technology Insights:
- Conjugate Vaccines
- Inactivated and Subunit Vaccines
- Live Attenuated Vaccines
- Recombinant Vaccines
- Toxoid Vaccines
- Others
Patient Type Insights:
- Paediatric
- Adult
Indication Insights:
- Bacterial Diseases
- Meningococcal Disease
- Pneumococcal Disease
- Diphtheria/Tetanus/Pertussis (DPT)
- Tuberculosis
- Haemophilus Influenzae (Hib)
- Typhoid
- Others
- Viral Diseases
- Hepatitis
- Influenza
- Human Papillomavirus (HPV)
- Measles/Mumps/Rubella (MMR)
- Rotavirus
- Herpes Zoster
- Varicella
- Japanese Encephalitis
- Rubella
- Polio
- Rabies
- Dengue
- Others
Route of Administration Insights:
- Intramuscular and Subcutaneous Administration
- Oral Administration
- Others
Product Type Insights:
- Multivalent Vaccine
- Monovalent Vaccine
Treatment Type Insights:
- Preventive Vaccine
- Therapeutic Vaccine
Distribution Channel Insights:
- Hospital Pharmacies
- Retail Pharmacies
- Institutional Sales
- Others
End User Insights:
- Hospitals
- Clinics
- Vaccination Centers
- Academic and Research Institutes
- Others
Regional Insights:
- Australia Capital Territory & New South Wales
- Victoria and Tasmania
- Queensland
- Northern Territory & Southern Australia
- Western Australia
Key Players
- CSL Seqirus
- Moderna
Recent Development & News
- February 2026: Australia recorded record whooping cough case levels, with about 54,000 cases reported in 2024 and nearly 800 cases per 100,000 children during 2024–25. Health authorities attributed the surge partly to declining vaccination uptake, reinforcing the importance of sustained immunisation campaigns and booster coverage across the population.
- January 2026: Health alerts were issued following a rise in measles infections across multiple Australian states, with 168 cases reported in 2025 versus 57 in 2024 and childhood vaccination coverage for two-year-olds falling to 89.7%, below the 95% herd-immunity threshold. The trend highlights ongoing challenges in maintaining vaccine coverage levels.
- September 2025: Australia approved the world’s first vaccine for koalas against chlamydia, a major conservation breakthrough targeting a disease affecting up to 50–70% of wild koalas in some regions. The vaccine is expected to reduce mortality and represents continued innovation and research activity within the country’s vaccine ecosystem.
- January 2026: Following a lumpy skin disease outbreak in Bali, Australian authorities strengthened biosecurity preparedness and supported regional response efforts, including provision of over 1.4 million vaccine doses to Indonesia to protect livestock and prevent cross-border disease spread.
Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Speak to an analyst for customized sample report: https://www.imarcgroup.com/request?type=report&id=32305&flag=C
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201-971-6302
